|  | Galcanezumab | ||
---|---|---|---|---|
Event | Placebo N=1451 n (%) | 120-mg N=705 n (%) | 240-mg N=730 n (%) | Combined N=1435 n (%) |
Injection site pain | 138 (9.5) | 71 (10.1) | 85 (11.6) | 156 (10.9) |
Nasopharyngitis | 94 (6.5) | 52 (7.4) | 31 (4.3)†| 83 (5.8) |
Upper respiratory tract infection | 60 (4.1) | 31 (4.4) | 36 (4.9) | 67 (4.7) |
Injection site reaction | 14 (1.0) | 22 (3.1)‡ | 45 (6.2)‡ | 67 (4.7)‡ |
Dizziness | 41 (2.8) | 20 (2.8) | 20 (2.7) | 40 (2.8) |
Injection site erythema | 20 (1.4) | 20 (2.8)†| 29 (4.0)‡ | 49 (3.4)‡ |
Sinusitis | 31 (2.1) | 20 (2.8) | 19 (2.6) | 39 (2.7) |
Urinary tract infection | 33 (2.3) | 19 (2.7) | 18 (2.5) | 37 (2.6) |
Fatigue | 34 (2.4) | 17 (2.4) | 16 (2.2) | 33 (2.3) |
Injection site pruritus | 2 (0.1) | 15 (2.1)‡ | 24 (3.3)‡ | 39 (2.7)‡ |
Neck pain | 21 (1.5) | 15 (2.1) | 6 (0.8) | 21 (1.5) |
Abdominal pain | 24 (1.7) | 13 (1.8) | 6 (0.8) | 19 (1.3) |
Cough | 19 (1.3) | 12 (1.7) | 13 (1.8) | 25 (1.7) |
Oropharyngeal pain | 13 (0.9) | 10 (1.4) | 12 (1.6) | 22 (1.5) |
Bronchitis | 17 (1.2) | 9 (1.3) | 11 (1.5) | 20 (1.4) |
Influenza | 34 (2.3) | 8 (1.1) | 20 (2.7) | 28 (2.0) |
Constipation | 8 (0.6) | 7 (1.0) | 11 (1.5)†| 18 (1.3)†|
Migraine | 14 (1.0) | 7 (1.0) | 12 (1.6) | 19 (1.3) |